Injectables in foam, new pharmaceutical applications

• US 8,512,680 B2
• Filed: 07/16/2007
• Issued: 08/20/2013
• Est. Priority Date: 08/08/2001
• Status: Expired due to Term

• Current Assignee: Biocompatibles Incorporated (Boston Scientific Corporation)
• Original Assignee: BTG International Limited (Boston Scientific Corporation)
• Inventors: Garca-Olmedo Dominguez, Mara Antonia
• Primary Examiner(s): Sullivan, Daniel
• Assistant Examiner(s): FRAZIER, BARBARA S
• Application Number:
  US11/879,215
• Publication Number:
  US 20080031827A1
• Time in Patent Office: 2,227 Days
• Field of Search: None
• US Class Current: 424/43
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/122 Foams; Dry foams edible foams A61K9/0056
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The placing of a drug that is suitable for parenteral administration on bubbles formed with sterile gases produces an exponential increase in its active surface area with a decrease in the diameter of the bubble, modifies the kinetics of its distribution and, thanks to its micronization, increases its therapeutic effect. Furthermore, the echogenicity of the bubbles allows us to follow them on ultrasound after their injection, so that we can visualise the medicament and, thanks to its steerability, can direct it to the selected site or prevent it from reaching undesired areas. This pharmaceutical form is of interest in the treatment of diseases that require a greater local action of the injected drugs than can be achieved with the pharmaceutical forms in current use.

Claims

1. A foam comprising a liquid phase and a gas phase;

wherein the liquid phase comprises at least one medicinal agent selected from the group consisting of fibrinolytics and thrombolytics and the liquid phase does not comprise encapsulated microspheres;

wherein the at least one medicinal agent is present in a concentration effective to treat a thrombosis;

wherein the at least one medicinal agent is not a sclerosing agent; and

wherein the foam is not a dispersion of microbubbles in the liquid phase at the time of injection into a patient.

2. The foam of claim 1, wherein the liquid phase further comprises at least one foaming agent.

3. A method of treating a thrombosis comprising injecting an effective amount of a foam into a patient in need thereof and contacting the site of the thrombosis with the foam;

wherein the foam comprises a liquid phase and a gas phase;

wherein the liquid phase comprises at least one medicinal agent chosen from fibrinolytics and thrombolytics and the liquid phase does not comprise encapsulated microspheres;

wherein the at least one medicinal agent is present in a concentration effective to treat a thrombosis;

wherein the at least one medicinal agent is not a sclerosing agent; and

wherein the foam is not a dispersion of microbubbles in the liquid phase at the time of injection into a patient.

4. The method of claim 3 wherein the liquid phase further comprises at least one foaming agent.